From the Guidelines
Ryaltris is a highly effective treatment option for seasonal allergic rhinitis, particularly for patients who do not respond adequately to single-ingredient allergy medications, due to its combination of olopatadine hydrochloride and mometasone furoate, which provides both quick relief and long-lasting symptom control 1.
Key Components of Ryaltris
- Olopatadine hydrochloride: an antihistamine that works quickly to block histamine receptors, providing fast relief from allergy symptoms like sneezing, itching, and runny nose.
- Mometasone furoate: a corticosteroid that reduces inflammation in the nasal passages for longer-lasting symptom control.
Dosage and Administration
- Standard dosage: two sprays in each nostril once daily.
- Prime the bottle before first use by pumping 6 times until a fine mist appears.
- Clean the nozzle regularly to prevent clogging.
Important Considerations
- Patients should avoid spraying directly onto the nasal septum.
- Ryaltris should not be used for more than 3 months continuously without medical supervision.
- Common side effects may include altered taste, nose bleeds, and headache.
Efficacy of Intranasal Corticosteroids
- Intranasal corticosteroids, such as mometasone furoate, are the most effective medication class in controlling symptoms of allergic rhinitis 1.
- They are more effective than the combined use of an antihistamine and a leukotriene antagonist in the treatment of seasonal allergic rhinitis 1.
Comparison with Other Treatments
- Ryaltris is particularly effective for patients who do not get adequate relief from single-ingredient allergy medications.
- The combination of olopatadine hydrochloride and mometasone furoate in Ryaltris provides a unique treatment approach that can address both quick relief and long-lasting symptom control.
From the Research
Ryaltris Overview
- Ryaltris is a combination nasal spray containing azelastine and fluticasone propionate, used for the treatment of allergic rhinitis 2.
- The combination of azelastine and fluticasone has shown superior efficacy in reducing nasal and ocular symptoms of allergic rhinitis compared to monotherapy with either azelastine or fluticasone 2, 3.
Efficacy of Ryaltris
- Studies have demonstrated that the combination of azelastine and fluticasone is more effective than monotherapy in reducing Total Nasal Symptom Score (TNSS) in patients with allergic rhinitis 4, 3.
- A systematic review and meta-analysis found that combination therapy with azelastine and fluticasone was superior to monotherapy or placebo in reducing TNSS and improving quality of life in patients with allergic rhinitis 3.
Comparison with Other Treatments
- Montelukast, an oral antihistamine, has been shown to be effective in treating allergic rhinitis, but is less effective than intranasal fluticasone spray in improving daytime and nighttime nasal symptom scores 5.
- The combination of montelukast and an oral antihistamine has been found to be superior to either montelukast or an oral antihistamine alone in improving symptoms of allergic rhinitis 5.
Treatment Recommendations
- Ryaltris is indicated for the treatment of moderate-to-severe seasonal allergic rhinitis and perennial allergic rhinitis when monotherapy with either intranasal antihistamine or intranasal corticosteroid is not considered sufficient 2.
- Combination therapy with azelastine and fluticasone should be considered as second-line therapy in patients with allergic rhinitis that is not controlled with monotherapy 3.